Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Shares Outstanding for 14 consecutive years, with $39.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 39.91% to $39.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.6 million through Dec 2025, up 39.91% year-over-year, with the annual reading at $29.0 million for FY2025, 7.29% up from the prior year.
  • Shares Outstanding hit $39.6 million in Q4 2025 for Vistagen Therapeutics, up from $38.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $206.6 million in Q4 2021 to a low of $1.1 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $27.0 million across 5 years, with a median of $19.5 million in 2023.
  • Biggest YoY gain for Shares Outstanding was 18160.19% in 2021; the steepest drop was 98.47% in 2021.
  • Year by year, Shares Outstanding stood at $206.6 million in 2021, then crashed by 96.66% to $6.9 million in 2022, then soared by 291.63% to $27.0 million in 2023, then grew by 4.78% to $28.3 million in 2024, then skyrocketed by 39.91% to $39.6 million in 2025.
  • Business Quant data shows Shares Outstanding for VTGN at $39.6 million in Q4 2025, $38.9 million in Q3 2025, and $29.3 million in Q2 2025.